Testimonials: Advancing Drug Discovery with AI & Data-Driven Innovation
At PozeSCAF Inc., we are revolutionizing drug discovery through our AI-powered platform – AxDrug and data-driven insights. Our expertise spans small molecule design, PROTACs, Molecular Glues, and custom synthesis, helping biopharma companies accelerate innovation from early-stage discovery to preclinical development.
Our clients and collaborators recognize our commitment to scientific excellence and cutting-edge technology. Here’s what they have to say about working with us:
What Our Clients Say
1. AI-Driven Small Molecule Discovery & Synthesis
“Our collaboration with PozeSCAF, which began in 2019, has been outstanding. By leveraging their AI-powered AxDrug platform and extensive computational chemistry expertise, we have successfully advanced multiple small molecule drug discovery projects. Their end-to-end capabilities, from AI-driven molecular design to synthesis services, have significantly accelerated our research timelines. The PozeSCAF team is highly receptive, demonstrates scientific excellence, and maintains a strong partnership approach, making them a trusted ally in our discovery efforts. We look forward to continuing this successful collaboration.”
Mohan R. Kaadige, PhD
Research Associate Professor
Translational Genomics Research Institute, part of City of Hope
Phoenix, AZ, USA
Date: February 10, 2025
2. AI-driven PROTACs design and synthesis
At Tuskegee University, we had the privilege of collaborating with PozeSCAF Inc. for our small molecule discovery needs, particularly in the hit-to-lead optimization phase and the design and evaluation of PROTACs.
PozeSCAF’s expertise in AI-driven drug discovery, computational chemistry, and synthetic chemistry was instrumental in accelerating our research. Their AxDrug platform provided deep computational insights, facilitating efficient hit identification, SAR analysis, and lead optimization. By integrating structure-based design, FEP-based ranking, and in silico ADMET prediction, we were able to prioritize the most promising candidates for synthesis with greater precision.
The PozeSCAF team demonstrated a strong understanding of the complexities of PROTAC development, including linker optimization and target engagement. Their synthesis capabilities and iterative design approach enabled us to advance key molecules efficiently, optimizing resource use while enhancing the probability of success.
Our partnership with PozeSCAF has been invaluable in streamlining our small molecule pipeline. Their combination of cutting-edge AI technology and medicinal chemistry expertise makes them an excellent partner for companies engaged in small molecule drug discovery and PROTAC development.
With bi-weekly interactions, our collaboration has been seamless, ensuring clear communication and steady progress. PozeSCAF’s responsiveness, scientific expertise, and commitment to excellence have made this partnership highly effective.
We appreciate PozeSCAF’s professionalism, transparency, timely deliverables, and scientific rigor and look forward to continued collaboration in the future.
Balu Karanam Ph.D
Associate Professor
Department of Biology and Cancer Research
Tuskegee University
Tuskegee, AL, USA
Date: February 10, 2025
3. Custom Synthesis
I had the opportunity to collaborate with PozeSCAF on synthesizing small molecules for our
upcoming product development, and I was impressed with their expertise, professionalism,
and commitment to quality. The team ensured timely delivery, seamless communication, and
a high standard of work, making our experience highly positive.
I look forward to future collaborations with them and would highly recommend their services
to others in the industry.
Manush Saydmohammed, Ph.D., MBA
Co-Founder & CEO
Zegenex Inc
Pittsburgh, PA, USA
Date: February 10, 2025